Tilting the balance of dose modification for oral anticancer drugs?

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1537-1539

  Bedard, Philippe L ^a   Siu, Lillian L ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PAZOPANIB; SORAFENIB; SUNITINIB; VEMURAFENIB;

CANCER CHEMOTHERAPY; EDITORIAL; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DOSE CALCULATION; METHODOLOGY; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG DOSAGE CALCULATIONS; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84903756548     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.2372     Document Type: Editorial

References (25)

1. Dunn R, Gochenauer G: The promise of oral anticancer agents: Addressing compliance and affordability. Oncol Bus Rev 6, 2012. http://obroncology.com/ obrgreen/article/The-Promise-of-Oral-Anticancer-Agents:-Addressing-Compliance- and-Affordability
2. Prasad V, Massey PR, Fojo T: Oral anticancer drugs: How limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 32:1620-1629, 2014
3. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
4. Motzer RJ, Nosov D, Eisen T, et al: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III trial. J Clin Oncol 31:3791-3799, 2013
5. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
6. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
7. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005 (Pubitemid 40300298)
8. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002 (Pubitemid 35266289)
9. Herbst RS, Maddox A-M, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
10. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002 (Pubitemid 34441651)
11. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003 (Pubitemid 37432975)
12. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL I trial). J Clin Oncol 21:2237-2246, 2003 (Pubitemid 46621858)
13. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004 (Pubitemid 41103588)
14. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004 (Pubitemid 41103589)
15. Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
16. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
17. Satoh H, Inoue A, Kobayashi K, et al: Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations. J Thorac Oncol 6:1413-1417, 2011
18. Gao B, Yeap S, Clements A, et al: Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017-4025, 2012
19. Rini BI, Schiller JH, Fruehauf JP, et al: Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clinical Cancer Res 17:3841-3849, 2011
20. Rini BI, Melichar B, Ueda T, et al: Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: A randomised double-blind phase 2 trial. Lancet Oncol 14:1233-1242, 2013
21. Péron J, Maillet D, Gan HK, et al: Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: A systematic review. J Clin Oncol 31:3957-3963, 2013
22. Sivendran S, Latif A, McBride RB, et al: Adverse event reporting in cancer clinical trial publications. J Clin Oncol 32:83-89, 2014
23. Ioannidis JP, Evans SJ, Gøtzsche PC, et al: Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 141:781-788, 2004 (Pubitemid 39524916)
24. Postel-Vinay S, Gomez-Roca C, Molife LR, et al: Phase I trials of molecularly targeted agents: Should we pay more attention to late toxicities? J Clin Oncol 29:1728-1735, 2011
25. Paoletti X, Le Tourneau C, Collette L, et al: Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of non-cytotoxic agents. ECCO-ESMO-ESTRO European Cancer Congress, Amsterdam, the Netherlands, September 27-October 1, 2013